Difference of Plasma Orexin A Levels Between Elderly and Young Patients at Emergence
To Investigate Difference of Plasma Orexin A Levels Between Elderly and Youth Patients at Emergence From Sevoflurane-fentanyl Anesthesia Undergoing Elective Lumbar Surgery
調査の概要
状態
条件
詳細な説明
BACKGROUND:A specific group of neurons in the brain produces hypocretin, also called orexin, a peptide which has been established as an important regulator of anesthesia and emergence in the latest few years. In the animal experiment,we found that the level of orexin A in aged rats was higher when compared with that of the young ones. Whereas the numbers of both the orexin receptor 1 and 2 in aged rats decreased. We wonder if there is a similar phenomenon in human beings which might account for the difference between the intervals of elderly and young patients recovering from anesthesia. This study aims to investigate difference of plasma orexin A levels between elderly patients and young at emergence from sevoflurane-fentanyl anesthesia.
DESIGNING:Forty patients with ASA physical status I or II scheduled for elective lumbar surgery under general anesthesia (lasting for 2h to 4h)were enrolled. Anesthesia was induced with propofol 1-1.5mg/kg and fentanyl 2-3μg/kg. Following muscle relaxation with iv rocuronium bromide 1mg/kg endotracheal intubation was performed. Anesthesia was maintained with sevoflurane(inhalational concentration: 0.8-1.5 MAC) fentanyl (total 6μg/kg) and target controlled infusion remifentanil (targeted concentration:2-7ng/ml ) along with an oxygen/air mixture (FiO2 = 0.5). Muscle relaxation was maintained with intermittent rocuronium. Inhalational concentration of sevoflurane and injected target concentration were titrated to maintain the bispectral index (BIS) between 45 and 65 during anesthesia. The end-tidal carbon dioxide level was maintained between 30 and 40mmHg by controlled mechanical ventilation. When the surgery was complicated we adjust the concentration sevoflurane to 0.8MAC of the patient and targeted concentration of remifentanil to 2ng/ml and then stop all anesthetics . Record time from stopping anesthetics to emergence. Arterial blood (2ml) was collected at the following time, such as before and 1h after induction of anesthesia, at emergence (1min after tracheal extubation) and half an hour after tracheal extubation. This was centrifuged at 3000 rpm for 15min at -4 ◦C in order to separate plasma then stored at -80 ◦C until assay for orexin A concentrations.
EXPECTED RESULTS:The plasma orexin A of group elderly will be higher with the emergence time longer than youth patients.
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710032
- 募集
- Anesthesiology department of Xijing Hospital
-
コンタクト:
- Zhihua Wang, postgraduate
- 電話番号:86-2984775343
- メール:xiangrikui038@sohu.com
-
主任研究者:
- Hailong Dong, MD,PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Participant is Adult (≥18 years old )
- Participants with a Body Mass Index (BMI) 20-25 kg/m2 at the prestudy (screening) visit.
- Participants with ASA physical status Ⅰor Ⅱ
- Participants with Heart function rating Ⅰor Ⅱ
- Glucose of patients is lower than 8 mmol/L
- patients will undergo elective lumbar surgery
Exclusion Criteria:
- Participant is a pregnant woman or a nursing mother.
- Participants have a history of narcotics allergic reactions
- indices of liver or kidney function is twice higher than normal
- Participants have a history or diagnosis of depression
- Participants have a history of Brain Trauma
- Participants have a history of narcotics addiction or drug addiction
- Participants have a history or diagnosis of adrenal gland diseases
- Participants or his family have an International Classification of Sleep Disorders diagnosis of OSA
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 時間の展望:見込みのある
コホートと介入
グループ/コホート |
|---|
|
elderly ,adult
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Hailong Dong, MD,PhD、Xijing Hospital
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- mzk2010orexin
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。